MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MC-232’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MC-232 is under development for the treatment of plaque psoriasis, bullous pemphigoid, hidradenitis suppurativa, atopic dermatitis. The drug candidate is administered topically and orally . It was under development for the treatment of non-small cell lung cancer, metastatic renal cell carcinoma and lymphomas. It is a synthetic small molecule that acts by targeting heat shock protein 90 (Hsp90). It is developed based on Heat Shock Protein (Hsp90) technology.
MC2 Therapeutics overview
MC2 Therapeutics is a privately held emerging pharmaceutical company. The company is headquartered in Hørsholm, Hovedstaden, Denmark.
For a complete picture of MC-232’s drug-specific PTSR and LoA scores, buy the report here.